Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170425 · ClinicalTrials.gov registry record
LAMBDA 002 (Lung Registry) Study
A clinical trial of Lung Transplant Rejection, sponsored by Natera.
- Active
- Registry status
- 154
- Enrollment target
- 11
- Study locations
NCT05170425: Active study of Lung Transplant Rejection, sponsored by Natera.
NCT05170425 is a study of Lung Transplant Rejection that is active but no longer recruiting, run by Natera. The registered enrollment target is 154 participants, below the 635-participant average among 6 other Lung Transplant Rejection trials with a reported enrollment target (76% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05170425, a study of Lung Transplant Rejection, is active but no longer recruiting, sponsored by Natera.
- ACTIVE NOT RECRUITING
- Registry status
- 154 participants
- Enrollment target
- 11
- Study locations
Study Summary
The LAMBDA 002 registry study is an observational, longitudinal, multi-center study observing patients undergoing lung transplant.
Conditions Studied
Interventions
- DEVICE Prospera
Study Locations (11)
Texas
- UT Southwestern Medical Center - Dallas
- Baylor College of Medicine Medical Center - Houston
- Houston Methodist Hospital - Houston
California
- Cedars-Sinai Medical Center - California City
Illinois
- Northwestern Memorial Hospital - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- Corewell Health - Grand Rapids
Missouri
- Washington University School of Medicine - St Louis
New York
- Columbia University Irving Medical Center - New York
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2027-05 |
What the registry record for NCT05170425 still lists
NCT05170425 is an observational study that tracks outcomes without assigning an intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 635-participant average among 6 other Lung Transplant Rejection trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Lung Transplant Rejection appearing as the primary indexed condition, and to 1 intervention - of which Prospera is the first listed.
NCT05170425 lists 11 locations in 9 states (Texas, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT05170425 about?
NCT05170425 is a clinical study titled "LAMBDA 002 (Lung Registry) Study". The LAMBDA 002 registry study is an observational, longitudinal, multi-center study observing patients undergoing lung transplant.
What is the current status of trial NCT05170425?
This trial is currently active not recruiting. The enrollment target is 154 participants. The study started on 2022-11-04. Estimated completion is 2027-05.
What conditions does trial NCT05170425 study?
This clinical trial studies the following conditions: Lung Transplant Rejection.
What interventions are being tested in trial NCT05170425?
The interventions under investigation include: Prospera (DEVICE).
Who is sponsoring clinical trial NCT05170425?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05170425 being conducted?
This trial has 11 study locations across California, Illinois, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
RECRUITING
-
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
RECRUITING
-
Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection
RECRUITING · Phase 2
-
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
RECRUITING · Phase 3
-
Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients
RECRUITING · NA
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI